Condition: Epilepsy Intractable · Sponsor: Duke University
The purpose of this study is to assess how well a new scoring system called the 5-SENSE score can predict where seizures start in the brain using Stereoelectroencephalography (SEEG). The 5-SENSE Score is a 5-point score based on routine presurgical work-up, designed to assist in predicting whether SEEG can identify a focal seizure onset zone, thereby sparing patients the risk of undergoing this invasive diagnostic procedure.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| University of Florida College of Medicine | Gainesville, Florida, United States | — |
| Northwestern University | Chicago, Illinois, United States | — |
| Duke University Health System | Durham, North Carolina, United States | — |
| Presbyterian-Shadyside Hospital | Pittsburgh, Pennsylvania, United States | — |
| Monash University | Melbourne, Victoria, Australia | — |
| Mater Health | Brisbane, Australia | — |
| Alfred Health | Melbourne, Australia | — |
| Christian Doppler University Hospital Paracelsus Medical University Salzburg and Centre for Cognitive Neuroscience Salzburg | Salzburg, Austria | — |
| Dalhousie Universiry and Hospital | Dalhousie, Nova Scotia, Canada | — |
| Wester University | London, Ontario, Canada | — |
| Departmet of Neurology, Masaryk University Brno | Brno, Czechia | — |
| Danish Epilepsy Centre, Aarhus Universitets Hospital | Aarhus, Denmark | — |
+ 7 more locations — full list on the registry record.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.